Goserelin versus orchiectomy in the treatment of advanced prostate cancer

Final results of a randomized trial

Nicholas J. Vogelzang, Gerald W. Chodak, Mark S. Soloway, Norman L Block, Paul F. Schellhammer, Joseph A. Smith, Richard J. Caplan, Gerard T. Kennealey

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

Objectives: To compare the efficacy and safety of goserelin and orchiectomy in patients with Stage D2 prostate cancer. Methods: A randomized, open, multicenter study was conducted in 283 patients. Patients were allocated to goserelin, 3.6 mg every 28 days, or to orchiectomy. Study end points were endocrine response, objective response, time to treatment failure, survival, and tolerability. Objective response was based on modified criteria of the National Prostate Cancer Project. Results: Serum testosterone decreased from baseline to castrate levels by week 4 in each group and remained below castrate levels thereafter. Acid phosphatase and alkaline phosphatase concentrations also decreased in each group. The goserelin and orchiectomy groups had similar results for objective response (82% versus 77%) and had similar median times to treatment failure (52 versus 53 weeks) and survival (119 versus 136 weeks). No significant interactions between treatments and prognostic factors were observed. Adjusting for baseline testosterone concentration had no effect on survival outcome. Race had no influence on outcome or efficacy end points. Common adverse events in both groups were pain, hot flushes, and lower urinary tract symptoms. Conclusions: Goserelin is well tolerated and as effective as orchiectomy in patients with Stage D2 prostate cancer.

Original languageEnglish
Pages (from-to)220-226
Number of pages7
JournalUrology
Volume46
Issue number2
DOIs
StatePublished - Jan 1 1995

Fingerprint

Goserelin
Orchiectomy
Prostatic Neoplasms
Treatment Failure
Survival
Testosterone
Lower Urinary Tract Symptoms
Therapeutics
Acid Phosphatase
Reaction Time
Multicenter Studies
Alkaline Phosphatase
Safety
Pain
Serum

ASJC Scopus subject areas

  • Urology

Cite this

Vogelzang, N. J., Chodak, G. W., Soloway, M. S., Block, N. L., Schellhammer, P. F., Smith, J. A., ... Kennealey, G. T. (1995). Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial. Urology, 46(2), 220-226. https://doi.org/10.1016/S0090-4295(99)80197-6

Goserelin versus orchiectomy in the treatment of advanced prostate cancer : Final results of a randomized trial. / Vogelzang, Nicholas J.; Chodak, Gerald W.; Soloway, Mark S.; Block, Norman L; Schellhammer, Paul F.; Smith, Joseph A.; Caplan, Richard J.; Kennealey, Gerard T.

In: Urology, Vol. 46, No. 2, 01.01.1995, p. 220-226.

Research output: Contribution to journalArticle

Vogelzang, NJ, Chodak, GW, Soloway, MS, Block, NL, Schellhammer, PF, Smith, JA, Caplan, RJ & Kennealey, GT 1995, 'Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial', Urology, vol. 46, no. 2, pp. 220-226. https://doi.org/10.1016/S0090-4295(99)80197-6
Vogelzang NJ, Chodak GW, Soloway MS, Block NL, Schellhammer PF, Smith JA et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial. Urology. 1995 Jan 1;46(2):220-226. https://doi.org/10.1016/S0090-4295(99)80197-6
Vogelzang, Nicholas J. ; Chodak, Gerald W. ; Soloway, Mark S. ; Block, Norman L ; Schellhammer, Paul F. ; Smith, Joseph A. ; Caplan, Richard J. ; Kennealey, Gerard T. / Goserelin versus orchiectomy in the treatment of advanced prostate cancer : Final results of a randomized trial. In: Urology. 1995 ; Vol. 46, No. 2. pp. 220-226.
@article{74ff7321831343f991748f975dd8845b,
title = "Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial",
abstract = "Objectives: To compare the efficacy and safety of goserelin and orchiectomy in patients with Stage D2 prostate cancer. Methods: A randomized, open, multicenter study was conducted in 283 patients. Patients were allocated to goserelin, 3.6 mg every 28 days, or to orchiectomy. Study end points were endocrine response, objective response, time to treatment failure, survival, and tolerability. Objective response was based on modified criteria of the National Prostate Cancer Project. Results: Serum testosterone decreased from baseline to castrate levels by week 4 in each group and remained below castrate levels thereafter. Acid phosphatase and alkaline phosphatase concentrations also decreased in each group. The goserelin and orchiectomy groups had similar results for objective response (82{\%} versus 77{\%}) and had similar median times to treatment failure (52 versus 53 weeks) and survival (119 versus 136 weeks). No significant interactions between treatments and prognostic factors were observed. Adjusting for baseline testosterone concentration had no effect on survival outcome. Race had no influence on outcome or efficacy end points. Common adverse events in both groups were pain, hot flushes, and lower urinary tract symptoms. Conclusions: Goserelin is well tolerated and as effective as orchiectomy in patients with Stage D2 prostate cancer.",
author = "Vogelzang, {Nicholas J.} and Chodak, {Gerald W.} and Soloway, {Mark S.} and Block, {Norman L} and Schellhammer, {Paul F.} and Smith, {Joseph A.} and Caplan, {Richard J.} and Kennealey, {Gerard T.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/S0090-4295(99)80197-6",
language = "English",
volume = "46",
pages = "220--226",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Goserelin versus orchiectomy in the treatment of advanced prostate cancer

T2 - Final results of a randomized trial

AU - Vogelzang, Nicholas J.

AU - Chodak, Gerald W.

AU - Soloway, Mark S.

AU - Block, Norman L

AU - Schellhammer, Paul F.

AU - Smith, Joseph A.

AU - Caplan, Richard J.

AU - Kennealey, Gerard T.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Objectives: To compare the efficacy and safety of goserelin and orchiectomy in patients with Stage D2 prostate cancer. Methods: A randomized, open, multicenter study was conducted in 283 patients. Patients were allocated to goserelin, 3.6 mg every 28 days, or to orchiectomy. Study end points were endocrine response, objective response, time to treatment failure, survival, and tolerability. Objective response was based on modified criteria of the National Prostate Cancer Project. Results: Serum testosterone decreased from baseline to castrate levels by week 4 in each group and remained below castrate levels thereafter. Acid phosphatase and alkaline phosphatase concentrations also decreased in each group. The goserelin and orchiectomy groups had similar results for objective response (82% versus 77%) and had similar median times to treatment failure (52 versus 53 weeks) and survival (119 versus 136 weeks). No significant interactions between treatments and prognostic factors were observed. Adjusting for baseline testosterone concentration had no effect on survival outcome. Race had no influence on outcome or efficacy end points. Common adverse events in both groups were pain, hot flushes, and lower urinary tract symptoms. Conclusions: Goserelin is well tolerated and as effective as orchiectomy in patients with Stage D2 prostate cancer.

AB - Objectives: To compare the efficacy and safety of goserelin and orchiectomy in patients with Stage D2 prostate cancer. Methods: A randomized, open, multicenter study was conducted in 283 patients. Patients were allocated to goserelin, 3.6 mg every 28 days, or to orchiectomy. Study end points were endocrine response, objective response, time to treatment failure, survival, and tolerability. Objective response was based on modified criteria of the National Prostate Cancer Project. Results: Serum testosterone decreased from baseline to castrate levels by week 4 in each group and remained below castrate levels thereafter. Acid phosphatase and alkaline phosphatase concentrations also decreased in each group. The goserelin and orchiectomy groups had similar results for objective response (82% versus 77%) and had similar median times to treatment failure (52 versus 53 weeks) and survival (119 versus 136 weeks). No significant interactions between treatments and prognostic factors were observed. Adjusting for baseline testosterone concentration had no effect on survival outcome. Race had no influence on outcome or efficacy end points. Common adverse events in both groups were pain, hot flushes, and lower urinary tract symptoms. Conclusions: Goserelin is well tolerated and as effective as orchiectomy in patients with Stage D2 prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0028875365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028875365&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(99)80197-6

DO - 10.1016/S0090-4295(99)80197-6

M3 - Article

VL - 46

SP - 220

EP - 226

JO - Urology

JF - Urology

SN - 0090-4295

IS - 2

ER -